Dr. Linda L. Garland

Doctor Overview

Dr. Linda Garland is a thoracic medical oncologist and translational researcher with expertise in mesothelioma. She currently serves as both the Co-Investigator & Medical Director of N01-Supported Cancer Center’s Cancer Prevention and Control Program and as the PI on Sequential NCI-Funded Lung Cancer Prevention Trials. Dr. Garland also works as a professor of medicine, specifically on the clinical-scholar track. She previously served for 10 years on the University of Arizona Institutional Review Board. Today, Dr. Garland serves as chair of the University of Arizona Cancer Center Scientific Review Committee.

Dr. Garland has built her career around searching for promising new ways to fight for cancer. Experimental therapeutics is the main focus of her research, particularly related to malignant diseases of the chest. She has developed and led translational clinical trials for novel targeted agents in advanced mesothelioma, as well as lung cancer. Her studies have investigated the efficacy of chemotherapy and focused on developing novel cancer therapies and biomarkers for earlier detection.

Doctor Fast Facts

Main Specialty: Thoracic Medical Oncology

Other Interests & Specialties: Oncology, hematologic oncology, lung cancer, non-small cell lung cancer, parathyroid cancer, small cell lung cancer, head and neck cancer, squamous cell carcinoma, thyroid cancer and mesothelioma.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, American Board of Internal Medicine Certification in Hematology, Chair of the University of Arizona Cancer Center Scientific Review Committee, member of The American College of Chest Physicians Task Force on Women and Girls, Tobacco, & Lung Cancer

Education & Experience:

• Medical Degree from University of Texas Health Science Center
• Residency for Internal Medicine at the University of South Florida College of Medicine
• Fellowship for Hematology/Oncology at H. Lee Moffitt Cancer Center

Publications

Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM). Journal of Thoracic Oncology. February 15;10(2):387–391. doi: 10.1097/JTO.0000000000000360

Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? The Annals of Thoracic Surgery. January 2019; 107(1):194 – 201. doi: 10.1016/j.athoracsur.2018.07.081

A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. Journal of Thoracic Oncology. March 2011;6(3):598–601. doi: 10.1097/JTO.0b013e318208c83d

Individualizing mesothelioma treatment: small steps into a brighter future. Clinical Lung Cancer. November 2010;11(6):371-3. doi: 10.3816/CLC.2010.n.048

Mesothelioma Clinical Trials by Linda L. Garland, MD

Dr. Linda L. Garland is associated with the following clinical trials: